TScan Therapeutics Inc. (TCRX), which continues to make meaningful progress across its pipeline, remains on track to provide a clinical update at the end of this year.
This clinical-stage biopharmaceutical company is developing T cell receptor-engineered T cell therapies (TCR-T) for the treatment of cancer. Patients' own T cells are genetically engineered to recognize and eliminate their cancer. Using one of its proprietary platform technologies, TargetScan, the company analyses the T cells of cancer patients with exceptional responses to immunotherapy to discover how the immune system naturally recognizes and eliminates tumor cells in these patients.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com